SBIR/STTR Research Award

Scalable, all-optical assays of synaptic function and plasticity

Award identifier 7333d32009da7feddf1a3bdf77d2c3355fc5abdfb352a408e129e9f29ca62267Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$764,645

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Q-State Biosciences, Inc.
Proposal award date
2017-01-12
Contract end date
2018-12-31
UEI
WWSMK3N4BCJ7
Solicitation number
PA14-197
Topic code
101

Research abstract

Project Summary In spite of the prevalence and severity of many neurological disordersthe development of new classes of drugs has been sluggish for decadesThe lack of new therapeutics is duein partto challenges in replicating the relevant biology in robustscalable in vitro assaysSynaptic dysfunctionin particularhas been implicated in a number of devastating neurological disorders including epilepsyAlzheimer s diseaseParkinson s diseaseAutism Spectrum DisorderASDschizophreniadepressionADHD and Huntington s diseaseCurrent approaches to measuring synaptic function suffer from the difficulty of stimulating the pre synaptic cell and recording from the post synaptic cell at a sufficient throughput for drug screeningThe Optopatch platform recently developed at Q State Biosciencescomprised of both engineered optogenetic proteinscustom microscopesand softwaremakes it possible to simultaneously stimulateblue lightand recordred lightelectrical activity from around one hundred neurons with one millisecond temporal resolutionsingle cell spatial resolution and high signal to noisePatterned blue light can be used to stimulate one or a larger subset of neurons while recording from all of the synaptic partnersUsing a custom engineered channelrhodopsin for stimulation in combination with red fluorescent sensors of voltagecalcium and pH targeted to preand post synaptic locationswe will develop a set of assays that span synaptic functionFurthermorewe will probe shortand long term synaptic plasticity using different stimulus regimesTo validate the assayswe will test know pharmacological modulators of synaptic machineryWe will also test for an in vitro phenotype for knockout of a post synaptic scaffolding proteinSHANKwhose loss of function has been implicated in ASD and schizophreniaWe will use both mouse and human iPSC based models of diseased neuronsThese optical toolswhich can scale to high throughputhave the potential to change the drug screening landscape for neurological disordersWe hope to open a new path to finding treatments for these devastating diseases

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

17 SBIR/STTR records share this UEI (2014–2020). Reported award amounts total $15,040,936. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.